Due to a variety of comorbidities, Patients with type 2 diabetes usually require a multifaceted approach to therapy. A large number of medications taken at the same time increases the risk of undesirable drug effects or drug interactions in the patient. It's vital to think about cytochrome P-450 (CYP) enzyme interactions while using a multifactorial pharmacotherapy approach. The cytochrome P450 enzymes CYP2C9 and CYP3A4 metabolise bosentan in the liver Similarly, glimepiride is metabolised in the liver by CYP2C9 to the active M1 (hydroxyl) metabolite and then to inactive M2 (carboxy) metabolite. This study was conducted to investigate a possible pharmacokinetic interaction between bosentan and glimepiride. Interaction of glimepiride, the known second-generation, long-acting insulin secretagogues agent with Bosentan, a pulmonary antihypertensive agent, In healthy and alloxan-induced diabetic rats, was tested. Blood samples were taken from rats at various intervals up to 24 hours and blood glucose levels were calculated. The parameters considered for the analysis of the effect of glimepiride-induced hypoglycemia were the onset of hypoglycemia, duration of hypoglycemia (duration of time in which more than 15 % - 20 % decrease in blood glucose level is managed to maintained), and peak hypoglycemia. In both healthy albino rats and diabetic rats, a single dose of bosentan did not affect blood glucose levels. These results suggest that bosentan has no hypoglycemic effect, implying that the drug-drug interaction with glimepiride is of the pharmacokinetic kind.